SARS-Cov-2 Infection in Severe Asthma Patients Treated With Biologics
Date
2022Language
en
Keyword
Abstract
Background: At the beginning of the pandemic, there have been considerable concerns regarding coronavirus disease 2019 (COVID-19) severity and outcomes in patients with severe asthma treated with biologics. Objective: To prospectively observe a cohort of severe asthmatics treated with biologics for the risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and disease severity during the COVID-19 pandemic. Methods: Physicians from centers treating patients with severe asthma all over Greece provided demographic and medical data regarding their patients treated with biologics. Physicians were also asked to follow up patients during the pandemic and to perform a polymerase chain reaction test in case of a suspected SARS-Cov-2 infection. Results: Among the 591 severe asthmatics (63.5% female) included in the study, 219 (37.1%) were treated with omalizumab, 358 (60.6%) with mepolizumab, and 14 (2.4%) with benralizumab. In total, 26 patients (4.4%) had a confirmed SARS-CoV-2 infection, 9 (34.6%) of whom were admitted to the hospital because of severe COVID-19, and 1 required mechanical ventilation and died 19 days after admission. Of the 26 infected patients, 5 (19.2%) experienced asthma control deterioration, characterized as exacerbation that required treatment with systemic corticosteroids. The scheduled administration of the biological therapy was performed timely in all patients with the exception of 2, in whom it was postponed for 1 week according to their doctors’ suggestion. Conclusion: Our study confirms that despite the initial concerns, SARS-CoV-2 infection is not more common in asthmatics treated with biologics compared with the general population, whereas the use of biologic treatments for severe asthma during the COVID-19 pandemic does not seem to be related to adverse outcomes from severe COVID-19. © 2022 American Academy of Allergy, Asthma & Immunology
Collections
Related items
Showing items related by title, author, creator and subject.
-
Cardiopulmonary exercise testing in patients with asthma: What is its clinical value?
Boutou A.K., Daniil Z., Pitsiou G., Papakosta D., Kioumis I., Stanopoulos I. (2020)Asthma is one of the most common respiratory disorders, characterized by fully or largely reversible airflow limitation. Asthma symptoms can be triggered or magnified during exertion, while physical activity limitation is ... -
Exhaled Nitric Oxide in Asthma in Adults: The End is the Beginning?
Kostikas, K.; Minas, M.; Papaioannou, A. I.; Papiris, S.; Dweik, R. A. (2011)Approximately 20 years after the initial report of the measurement of exhaled nitric oxide (NO) in the exhaled air of humans, numerous publications have evaluated the possible applications of the fraction of exhaled NO ... -
Impaired Cardiovascular Response to Exercise in Patients with Severe Asthma: A Case-Control Study
Georgopoulou A., Fotiadou L., Tryfon S., Daniil Z., Boutou A.K. (2022)Background: Although asthmatics may present reduced exercise capacity, data on their cardiovascular responses during exercise testing have been scarcely investigated. The aim of this pilot case-control study is to test: ...